

529,088

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)


PCT

(10) International Publication Number
WO 2004/029616 A2

- (51) International Patent Classification⁷: **G01N 33/48**
- (21) International Application Number:
PCT/CA2003/001479
- (22) International Filing Date:
26 September 2003 (26.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/414,314 26 September 2002 (26.09.2002) US
- (71) Applicant (for all designated States except US): **MOUNT SINAI HOSPITAL [CA/CA]**; 600 University Avenue, Toronto, Ontario M5G 1X5 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **DIAMANDIS, Eleftherios, P. [CA/CA]**; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA).
- (74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, Suite 4700, P.O. Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS FOR DETECTING PROSTATE CANCER



(57) Abstract: The invention relates to the application of kallikrein (11), free PSA, and total PSA in the detection of prostate cancer. These markers may be used for the diagnosis, monitoring, staging, progression, prevention, treatment, and prognosis of prostate cancer, and as indicators before surgery or after relapse. A particular aspect of the invention provides a method for distinguishing prostate cancer from benign prostatic hyperplasia (BPH).

WO 2004/029616 A2



Published:

— *without international search report and to be republished
upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.